Counseling patients about hormone therapy and alternatives for menopausal symptoms

American Family Physician

Volumn 82, Issue 7, 2010, Pages 801-807

  Hill, D Ashley ^a   Hill, Susan R ^b  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE; RALOXIFENE; BONE DENSITY CONSERVATION AGENT; PLANT MEDICINAL PRODUCT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR RISK; COLORECTAL CANCER; DOSE RESPONSE; HEART FUNCTION; HERBAL MEDICINE; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; PATIENT COUNSELING; PATIENT GUIDANCE; PATIENT PREFERENCE; POSTMENOPAUSE OSTEOPOROSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT PLANNING; VASOMOTOR DISORDER; WOMEN'S HEALTH; AGED; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; ESTROGEN THERAPY; FEMALE; HOT FLUSH; INTRAVAGINAL DRUG ADMINISTRATION; MIDDLE AGED; RISK FACTOR;

ADMINISTRATION, INTRAVAGINAL; AGED; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLANT PREPARATIONS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 78149474200     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA. 2003;289(5):537-538.
2. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol. 2008;112(5):1189-1192.
3. Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
4. Anderson GL, Limacher M, Assaf AR, et al.; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
5. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause [published correction appears in JAMA. 2008;299(12):1426]. JAMA. 2007;297(13):1465-1477.
6. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007;14(3 pt 1):373-384.
7. Manson JE, Allison MA, Rossouw JE, et al.; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591-2602.
8. Utian WH, Bachmann GA, Cahill EB, et al. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(2):242-255.
9. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force [published correction appears in Ann Intern Med. 2003;138(4):360]. Ann Intern Med. 2002;136(9):680-690.
10. Pilon D, Castilloux AM, LeLorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol. 2001;97(1):97-100.
11. Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? Menopause. 2009;16(3):494-499.
12. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52-86.
13. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 2006;355(22):2338-2347.
14. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978.
15. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291(13):1610-1620.
16. Canonico M, Oger E, Plu-Bureau G, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845.
17. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med. 2005;118(suppl 12B):74-78.
18. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;110(4):771-779.
19. Lethaby AE, et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007;(4):CD001395.
20. U.S. Food and Drug Administration. Pharmacy compounding. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/default.htm. Accessed December 30, 2009.
21. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 322: Compounded bioidentical hormones. Obstet Gynecol. 2005;106(5 pt 1):1139-1140.
22. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356(9247):2059-2063.
23. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101(2):337-345.
24. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;(4):CD001500.
25. Nikander E, et al. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women. Fertil Steril. 2005;83(1):137-142.
26. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(3):259-263.
27. Ettinger B, Black DM, Mitlak BH, et al.; Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial [published correction appears in JAMA. 1999;282(22):2124]. JAMA. 1999;282(7):637-645.
28. Barrett-Connor E, Mosca L, Collins P, et al.; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125-137.
29. Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs. 2000;60(2):379-411.